Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Lutz Jacobasch
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, L. Jacobasch wrote the following 2 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Clinical Trial CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. 2017

Sinn, Marianne / Bahra, Marcus / Liersch, Torsten / Gellert, Klaus / Messmann, Helmut / Bechstein, Wolf / Waldschmidt, Dirk / Jacobasch, Lutz / Wilhelm, Martin / Rau, Bettina M / Grützmann, Robert / Weinmann, Arndt / Maschmeyer, Georg / Pelzer, Uwe / Stieler, Jens M / Striefler, Jana K / Ghadimi, Michael / Bischoff, Sven / Dörken, Bernd / Oettle, Helmut / Riess, Hanno. ·Marianne Sinn, Marcus Bahra, Uwe Pelzer, Jens M. Stieler, Jana K. Striefler, Sven Bischoff, Bernd Dörken, and Hanno Riess, Charité-Universitätsmedizin Berlin · Klaus Gellert, Sana Klinikum Lichtenberg, Berlin · Torsten Liersch and Michael Ghadimi, Universitätsmedizin Göttingen, Göttingen · Helmut Messmann, Klinikum Augsburg, Augsburg · Wolf Bechstein, Universitätsklinikum Frankfurt, Frankfurt · Dirk Waldschmidt, Universitätsklinikum Köln, Köln · Lutz Jacobasch, Clinical Center, Dresden · Martin Wilhelm, Paracelsus Medical University, Nürnberg · Bettina M. Rau, Universitätsmedizin Rostock, and Municipal Hospital of Neumarkt, Rostock · Robert Grützmann, Universitätsklinikum Carl Gustav Carus, Dresden, and Universitätsklinikum Erlangen, Erlangen · Arndt Weinmann, Klinikum der Johannes Gutenberg-Universität, Mainz · Georg Maschmeyer, Ernst von Bergmann Klinikum, Potsdam · and Helmut Oettle, Clinical Center, Friedrichshafen, Germany. ·J Clin Oncol · Pubmed #28817370.

ABSTRACT: Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to improve survival in patients with primarily resectable PDAC after R0 resection. Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to one of two study arms: gemcitabine 1,000 mg/m

2 Article Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. 2019

Wittel, U A / Lubgan, D / Ghadimi, M / Belyaev, O / Uhl, W / Bechstein, W O / Grützmann, R / Hohenberger, W M / Schmid, A / Jacobasch, L / Croner, R S / Reinacher-Schick, A / Hopt, U T / Pirkl, A / Oettle, H / Fietkau, R / Golcher, H. ·Department for General- und Visceral Surgery, Medical Center and Faculty of Medicine University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany. uwe.wittel@unikklinik-freiburg.de. · Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Department of General, Visceral and Pediatric Surgery, Medical Center Georg-August-University Göttingen, Göttingen, Germany. · Department of Surgery, St. Josef Hospital Ruhr-University Bochum, Bochum, Germany. · Department of General and Visceral Surgery, Frankfurt University Hospital and Clinics, Frankfurt, Germany. · Department of Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Department of Radiology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Private Practice, Hematology/Oncology, Dresden, Germany. · Department of Surgery, University Hospital Magdeburg, Magdeburg, Germany. · Department for Hematology, Oncology and Palliative Care, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. · Department for General- und Visceral Surgery, Medical Center and Faculty of Medicine University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany. · Medical Centre for Information and Communication Technology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. · Outpatient Department Hematology/Oncology, Friedrichshafen, Germany. ·BMC Cancer · Pubmed #31640628.

ABSTRACT: BACKGROUND: One critical step in the therapy of patients with localized pancreatic cancer is the determination of local resectability. The decision between primary surgery versus upfront local or systemic cancer therapy seems especially to differ between pancreatic cancer centers. In our cohort study, we analyzed the independent judgement of resectability of five experienced high volume pancreatic surgeons in 200 consecutive patients with borderline resectable or locally advanced pancreatic cancer. METHODS: Pretherapeutic CT or MRI scans of 200 consecutive patients with borderline resectable or locally advanced pancreatic cancer were evaluated by 5 independent pancreatic surgeons. Resectability and the degree of abutment of the tumor to the venous and arterial structures adjacent to the pancreas were reported. Interrater reliability and dispersion indices were compared. RESULTS: One hundred ninety-four CT scans and 6 MRI scans were evaluated and all parameters were evaluated by all surgeons in 133 (66.5%) cases. Low agreement was observed for tumor infiltration of venous structures (κ = 0.265 and κ = 0.285) while good agreement was achieved for the abutment of the tumor to arterial structures (interrater reliability celiac trunk κ = 0.708 P < 0.001). In patients with vascular tumor contact indicating locally advanced disease, surgeons highly agreed on unresectability, but in patients with vascular tumor abutment consistent with borderline resectable disease, the judgement of resectability was less uniform (dispersion index locally advanced vs. borderline resectable p < 0.05). CONCLUSION: Excellent agreement between surgeons exists in determining the presence of arterial abutment and locally advanced pancreatic cancer. The determination of resectability in borderline resectable patients is influenced by additional subjective factors. TRIAL REGISTRATION: EudraCT:2009-014476-21 (2013-02-22) and NCT01827553 (2013-04-09).